[go: up one dir, main page]

MX366677B - Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas. - Google Patents

Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas.

Info

Publication number
MX366677B
MX366677B MX2014012888A MX2014012888A MX366677B MX 366677 B MX366677 B MX 366677B MX 2014012888 A MX2014012888 A MX 2014012888A MX 2014012888 A MX2014012888 A MX 2014012888A MX 366677 B MX366677 B MX 366677B
Authority
MX
Mexico
Prior art keywords
polymeric material
drug
core
layer
inner layer
Prior art date
Application number
MX2014012888A
Other languages
English (en)
Other versions
MX2014012888A (es
Inventor
Carlos Bravo González Roberto
Buser Thomas
Jean-Claude Goutte Frédéric
Waseh Basit Abdul
José Oliveria Varum Felipe
Cristina Freire Ana
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366677(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MX2014012888A publication Critical patent/MX2014012888A/es
Publication of MX366677B publication Critical patent/MX366677B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Grain Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La liberación retardada de un fármaco al colon se logra de una formulación de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo. El núcleo comprende un fármaco y un recubrimiento que comprende una capa interior y al menos una capa entre el núcleo y la capa exterior seleccionada del grupo que consiste de una capa de aislamiento y una capa interior. La capa exterior comprende una mezcla de un primer material polimérico que es susceptible a ataques por parte de la bacteria colónica, y un segundo material polimérico que tiene un umbral de pH a aproximadamente pH 5 o más alto. La capa interior comprende un tercer material polimérico que es soluble en el fluido intestinal o en el fluido gastrointestinal, tal tercer material polimérico se selecciona de ácido policarboxílico al menos parcialmente neutralizado y un polímero no iónico. En modalidades en donde el tercer material polimérico es un polímero no iónico, la capa interior comprende al menos un agente amortiguador y una base. La capa de aislamiento comprende un polímero no iónico que es soluble en el fluido intestinal o fluido gastrointestinal. El exterior es un medio acuoso con un segundo material polimérico en un medio orgánico. Las ventajas de las formulaciones de acuerdo con la presente invención incluyen la liberación acelerada del fármaco cuando se expone a condiciones colónicas y la reducción o eliminación del efecto de los alimentos y/o alcohol en la liberación del fármaco después de la administración.
MX2014012888A 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas. MX366677B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261640217P 2012-04-30 2012-04-30
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation
PCT/EP2013/058923 WO2013164316A1 (en) 2012-04-30 2013-04-29 A delayed release drug formulation

Publications (2)

Publication Number Publication Date
MX2014012888A MX2014012888A (es) 2015-04-13
MX366677B true MX366677B (es) 2019-07-19

Family

ID=46025554

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014012888A MX366677B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas.
MX2018010476A MX373249B (es) 2012-04-30 2013-04-29 Formulacion de farmaco de liberacion retardada que comprende un nucleo y un recubrimiento multicapa para el nucleo que comprende al menos tres capas polimericas.
MX2014012887A MX362529B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento multicapa para el núcleo que comprende al menos tres capas poliméricas.
MX2018010475A MX367127B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2018010476A MX373249B (es) 2012-04-30 2013-04-29 Formulacion de farmaco de liberacion retardada que comprende un nucleo y un recubrimiento multicapa para el nucleo que comprende al menos tres capas polimericas.
MX2014012887A MX362529B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento multicapa para el núcleo que comprende al menos tres capas poliméricas.
MX2018010475A MX367127B (es) 2012-04-30 2013-04-29 Formulación de fármaco de liberación retardada que comprende un núcleo y un recubrimiento para el núcleo que comprende al menos dos o tres capas poliméricas.

Country Status (41)

Country Link
US (6) US9364440B2 (es)
EP (6) EP2659881B1 (es)
JP (2) JP6621662B2 (es)
KR (6) KR102177773B1 (es)
CN (5) CN110237056B (es)
AR (1) AR090898A1 (es)
AU (4) AU2013255913B2 (es)
BR (3) BR112014026935A2 (es)
CA (4) CA3080035A1 (es)
CL (2) CL2014002796A1 (es)
CO (2) CO7141433A2 (es)
CR (4) CR20190246A (es)
CU (1) CU24304B1 (es)
CY (4) CY1120215T1 (es)
DK (5) DK2659881T3 (es)
EA (2) EA032514B1 (es)
ES (6) ES2655622T3 (es)
GE (4) GEP201706753B (es)
HR (2) HRP20180068T1 (es)
HU (5) HUE036187T2 (es)
JO (6) JOP20200144A1 (es)
LT (5) LT2659881T (es)
ME (2) ME03364B (es)
MX (4) MX366677B (es)
MY (3) MY169088A (es)
NO (1) NO2659881T3 (es)
NZ (3) NZ629260A (es)
PE (3) PE20150129A1 (es)
PH (2) PH12014502340A1 (es)
PL (5) PL2659881T3 (es)
PT (5) PT2659881T (es)
RS (5) RS56839B1 (es)
SA (2) SA113340508B1 (es)
SG (2) SG11201406798WA (es)
SI (5) SI2659881T1 (es)
SM (5) SMT201800095T1 (es)
TN (2) TN2014000442A1 (es)
TR (3) TR201905226T4 (es)
TW (3) TWI618547B (es)
UY (1) UY34772A (es)
WO (2) WO2013164316A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20192210T1 (hr) * 2012-04-30 2020-02-21 Tillotts Pharma Ag Formulacija lijeka s produženim otpuštanjem
JOP20200144A1 (ar) * 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
PT2959892T (pt) * 2013-02-22 2020-12-15 Zeria Pharm Co Ltd Comprimido com revestimento entérico
BR122020013726B1 (pt) 2013-10-29 2022-11-01 Tillotts Pharma Ag Formulação de droga de liberação retardada
EP3086776B1 (en) 2013-12-24 2020-06-17 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
AU2016271303C1 (en) 2015-06-01 2022-04-14 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
US11311573B2 (en) * 2016-11-30 2022-04-26 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
EP3768245A4 (en) * 2018-03-23 2023-10-18 Palatin Technologies, Inc. MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS FOR GASTROINTESTINAL TRACT-SPECIFIC ADMINISTRATION
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
EP3662901B1 (en) 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662900A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662902B1 (en) 2018-12-07 2024-07-31 Tillotts Pharma AG Colonic drug delivery formulation
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
ES2906316T3 (es) * 2018-12-10 2022-04-18 Aphaia Ip Ag Formas farmacéuticas de dosificación oral para el tratamiento de trastornos metabólicos y enfermedades relacionadas mediante la liberación orquestada de enterocinas
CN111617047B (zh) * 2019-02-27 2021-06-22 广州喜鹊医药有限公司 一种含tbn或其盐或其水合物的药物组合物及其制备方法
GB201905940D0 (en) * 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
CA3148226A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
CN115461046A (zh) * 2019-11-13 2022-12-09 爱的发制药集团 用于生产具有结肠递送的口服施用药物组合物的方法
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
EP4180031B1 (en) * 2020-07-13 2025-10-22 Kirin Holdings Kabushiki Kaisha Film coated tablet
US20240293429A1 (en) * 2021-06-01 2024-09-05 Nbi Biosciences Pvt Ltd Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof
CN117024341A (zh) * 2022-04-30 2023-11-10 宁波大学 一类d-2a不对称型热活化延迟荧光材料的合成及其应用
CN116898823A (zh) * 2023-08-02 2023-10-20 中国农业大学 一种微囊结构及其制备方法和应用
WO2025082974A1 (en) * 2023-10-16 2025-04-24 Bioprojet Pharma New formulations of pitolisant and methods of use
CN118806729B (zh) * 2024-06-18 2025-04-22 海南合瑞制药股份有限公司 美沙拉秦肠溶缓释微丸及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) * 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
EP0667148B1 (en) * 1992-11-06 2002-07-03 Hisamitsu Pharmaceutical Co., Inc. Peroral pharmaceutical preparation releasable in lower digestive tract
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
EP1108431B1 (en) * 1999-12-16 2003-05-02 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Gastroresistant multi-unitary pharmaceutical preparations containing piroxicam
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780L (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
EP1391200A4 (en) 2001-05-25 2004-06-16 Ssp Co Ltd DRUG
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
CN1964704A (zh) * 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2007034503A2 (en) 2005-06-20 2007-03-29 Cadila Healthcare Limited Controlled release dosage formulation of duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
WO2008020286A2 (en) 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
US20100179170A1 (en) * 2006-12-05 2010-07-15 Lisa Claire Du Toit Heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
EP2143424A4 (en) * 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
KR101443943B1 (ko) 2007-05-07 2014-10-07 에보니크 룀 게엠베하 가속된 약물 방출을 갖는 장용 코팅을 포함하는 고체 투여 형태
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) * 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US20130259947A1 (en) 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
WO2013035081A2 (de) 2011-09-07 2013-03-14 JÄNISCH, Melisa Optimale formulierung zur freisetzung eines wirkstoffes im dickdarm
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
JOP20200144A1 (ar) * 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
BR122020013726B1 (pt) 2013-10-29 2022-11-01 Tillotts Pharma Ag Formulação de droga de liberação retardada

Also Published As

Publication number Publication date
KR20200073296A (ko) 2020-06-23
JOP20200146B1 (ar) 2023-09-17
US20140056980A1 (en) 2014-02-27
CY1120215T1 (el) 2018-12-12
LT3278792T (lt) 2019-05-10
CR20140485A (es) 2015-01-19
CN110237056A (zh) 2019-09-17
WO2013164315A1 (en) 2013-11-07
ES2987408T3 (es) 2024-11-14
TWI618547B (zh) 2018-03-21
JO3574B1 (ar) 2020-07-05
EA032514B1 (ru) 2019-06-28
DK2844220T3 (en) 2019-04-08
LT2844222T (lt) 2019-12-27
EP3187171C0 (en) 2024-09-25
US10226430B2 (en) 2019-03-12
CR20190246A (es) 2019-09-03
AU2017210571A1 (en) 2017-08-24
NZ629262A (en) 2017-01-27
EA201491783A1 (ru) 2014-12-30
JOP20200147A1 (ar) 2022-10-30
TW201343202A (zh) 2013-11-01
SG11201406799XA (en) 2014-11-27
CO7141433A2 (es) 2014-12-12
KR20190127984A (ko) 2019-11-13
US11534406B2 (en) 2022-12-27
AU2013255913A1 (en) 2014-11-13
JP6621661B2 (ja) 2019-12-18
HUE037702T2 (hu) 2018-09-28
PE20150129A1 (es) 2015-02-13
AU2013255914A1 (en) 2014-11-13
EP2844222A1 (en) 2015-03-11
KR102102198B1 (ko) 2020-04-21
CY1122475T1 (el) 2021-01-27
TR201905226T4 (tr) 2019-05-21
GEP201706736B (en) 2017-09-25
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
CR20140486A (es) 2015-01-19
CL2014002796A1 (es) 2015-02-06
PT2659881T (pt) 2018-01-29
EP2844220B1 (en) 2019-01-23
EP2844222B1 (en) 2019-11-13
RS59697B1 (sr) 2020-01-31
US20150125525A1 (en) 2015-05-07
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
PT3278792T (pt) 2019-05-23
ES2714448T3 (es) 2019-05-28
EP2844220A1 (en) 2015-03-11
CL2014002795A1 (es) 2015-02-13
CN110200949B (zh) 2021-11-16
KR102177773B1 (ko) 2020-11-12
SI2844222T1 (sl) 2020-02-28
EP3189830B1 (en) 2018-05-23
BR112014026933A2 (pt) 2017-06-27
CN106983735A (zh) 2017-07-28
MX2014012887A (es) 2015-05-08
PE20190625A1 (es) 2019-04-26
US20200214987A1 (en) 2020-07-09
SMT201900215T1 (it) 2019-05-10
NO2659881T3 (es) 2018-04-28
TW202037370A (zh) 2020-10-16
BR112014026933B1 (pt) 2022-07-19
SI2844220T1 (sl) 2019-05-31
PT2844220T (pt) 2019-03-27
BR112014026935A2 (pt) 2017-06-27
LT2844220T (lt) 2019-04-10
CA3080035A1 (en) 2013-11-07
TR201809416T4 (tr) 2018-07-23
PL2844222T3 (pl) 2020-03-31
PH12014502340B1 (en) 2014-12-22
US20150132380A1 (en) 2015-05-14
AU2013255914B2 (en) 2017-08-31
RS58735B1 (sr) 2019-06-28
LT2659881T (lt) 2018-02-12
ES2761341T3 (es) 2020-05-19
AR090898A1 (es) 2014-12-17
UY34772A (es) 2013-11-29
JP6621662B2 (ja) 2019-12-18
PT2844222T (pt) 2019-12-30
MX367127B (es) 2019-08-06
KR102104070B1 (ko) 2020-04-24
CN104302274A (zh) 2015-01-21
NZ725409A (en) 2018-05-25
SMT201800360T1 (it) 2018-09-13
KR20190127986A (ko) 2019-11-13
KR20150004910A (ko) 2015-01-13
JOP20200148B1 (ar) 2023-09-17
TWI705833B (zh) 2020-10-01
US20170035698A1 (en) 2017-02-09
DK2659881T3 (en) 2018-02-05
SMT202000014T1 (it) 2020-03-13
US20170266117A1 (en) 2017-09-21
NZ629260A (en) 2017-01-27
RS57431B1 (sr) 2018-09-28
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (en) 2018-03-30
HUE036187T2 (hu) 2018-06-28
JOP20200145B1 (ar) 2023-09-17
SMT201900252T1 (it) 2019-07-11
GEP201706753B (en) 2017-10-25
CR20190245A (es) 2019-07-29
LT3189830T (lt) 2018-07-10
JOP20200147B1 (ar) 2023-09-17
EA032811B1 (ru) 2019-07-31
ME03364B (me) 2019-10-20
CA3052460C (en) 2022-06-07
MX362529B (es) 2019-01-23
SA115370043B1 (ar) 2016-05-24
CA2871016C (en) 2023-03-21
CU20140123A7 (es) 2015-02-26
JP2015515964A (ja) 2015-06-04
HUE043238T2 (hu) 2019-08-28
CA3052460A1 (en) 2013-11-07
PL3189830T3 (pl) 2018-11-30
EP3189830A1 (en) 2017-07-12
MX373249B (es) 2020-05-12
TWI700102B (zh) 2020-08-01
SI3278792T1 (sl) 2019-06-28
JP2015515965A (ja) 2015-06-04
CY1120492T1 (el) 2019-07-10
PT3189830T (pt) 2018-10-19
AU2017210571B2 (en) 2018-11-29
EA201491781A1 (ru) 2014-12-30
HUE042833T2 (hu) 2019-07-29
ES2720258T3 (es) 2019-07-19
GEP201706758B (en) 2017-10-25
EP3278792B1 (en) 2019-02-20
SI3189830T1 (en) 2018-08-31
GEP201706759B (en) 2017-10-25
JOP20200148A1 (ar) 2022-10-30
SMT201800095T1 (it) 2018-03-08
BR122019022551B1 (pt) 2022-07-19
RS56839B1 (sr) 2018-04-30
CN110200949A (zh) 2019-09-06
DK3278792T3 (da) 2019-05-06
RS58625B1 (sr) 2019-05-31
CU24304B1 (es) 2018-01-10
PL3278792T3 (pl) 2019-09-30
WO2013164316A1 (en) 2013-11-07
CA2871016A1 (en) 2013-11-07
PH12014502339A1 (en) 2014-12-22
ES2673931T3 (es) 2018-06-26
TW201720430A (zh) 2017-06-16
TR201903569T4 (tr) 2019-04-22
CN110237056B (zh) 2022-03-08
DK3189830T3 (en) 2018-07-16
JOP20200145A1 (ar) 2022-10-30
HUE046628T2 (hu) 2020-03-30
PH12014502339B1 (en) 2014-12-22
TN2014000441A1 (en) 2016-03-30
US10272048B2 (en) 2019-04-30
US9814681B2 (en) 2017-11-14
TN2014000442A1 (en) 2016-03-30
ME03641B (me) 2020-07-20
DK2844222T3 (da) 2019-12-09
ES2655622T3 (es) 2018-02-20
CA2871017A1 (en) 2013-11-07
CN104271113B (zh) 2019-03-22
PH12014502340A1 (en) 2014-12-22
HRP20180965T1 (hr) 2018-08-10
PE20142442A1 (es) 2015-01-28
US9364440B2 (en) 2016-06-14
AU2017210577A1 (en) 2017-08-24
EP3278792A1 (en) 2018-02-07
MY169161A (en) 2019-02-19
SG11201406798WA (en) 2014-11-27
AU2013255913B2 (en) 2017-08-31
PL2659881T3 (pl) 2018-05-30
CN104271113A (zh) 2015-01-07
AU2017210577B2 (en) 2018-11-29
US11517534B2 (en) 2022-12-06
EP3187171B1 (en) 2024-09-25
KR20150004911A (ko) 2015-01-13
EP2659881A1 (en) 2013-11-06
KR20200075024A (ko) 2020-06-25
MY190392A (en) 2022-04-20
JOP20200144A1 (ar) 2017-06-16
EP3187171A1 (en) 2017-07-05
JOP20200146A1 (ar) 2022-10-30
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
CY1121609T1 (el) 2020-05-29
CO7151506A2 (es) 2014-12-29

Similar Documents

Publication Publication Date Title
JOP20200148B1 (ar) تركيبة عقار ذو إطلاق متأخر
NZ717159A (en) A delayed release drug formulation
PH12018501311A1 (en) A delayed release drug formulation
TH148827A (th) สูตรผสมยาชนิดปลดปล่อยแบบชะลอ
CU24302B1 (es) Formulación de fármaco de liberación retardada

Legal Events

Date Code Title Description
FG Grant or registration